



## Personalis, Inc. Announces New Data to be Presented at ASCO Virtual Scientific Meeting

May 29, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--May 29, 2020--Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced that the company will present new data in abstracts to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, which will be held May 29-31, 2020.

One abstract showcases data from the [ImmunolD NeXT Platform™](#), the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunolD NeXT can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

Another abstract highlights data from the Personalis [NeXT Dx™ Test](#), one of the first cancer diagnostic platforms to profile approximately 20,000 genes in both the tumor exome and transcriptome, providing a comprehensive genomic testing solution that goes beyond many existing cancer diagnostic panels that focus on a few hundred genes. The Personalis NeXT Dx Test includes advanced analytics to provide a diagnostic report on genetic alterations in clinically-important cancer genes, as well as emerging immunotherapy composite biomarkers of medical importance.

Following are details and links to the abstracts that will be presented at the online meeting.

Abstract Number & Session Title	Title & Presenter	Date	Location
6557 Head and Neck Cancers	<a href="#">Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck.</a> Presenter: Charles Abbott	May 29, 2020	<a href="#">Online</a>
e15583 Developmental Therapeutics —Molecularly Targeted Agents and Tumor Biology	<a href="#">Validation of an exome and transcriptome based diagnostic platform enabling clinical cancer therapy selection and emerging composite biomarkers for immunotherapy.</a> Presenter: Sebastian Saldivar	May 29, 2020	<a href="#">Online</a>

### About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis [ImmunolD NeXT Platform™](#) is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis [Clinical Laboratory](#) is GxP-aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit [www.personalis.com](http://www.personalis.com) and follow Personalis on Twitter ([@PersonalisInc](#)).

### Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding the future availability, features or potential uses of the ImmunolD NeXT Platform or NeXT Dx Test and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis' filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200529005485/en/): <https://www.businesswire.com/news/home/20200529005485/en/>

### Investor Relations Contact for Personalis:

Caroline Corner  
[investors@personalis.com](mailto:investors@personalis.com)  
415-202-5678

### Media Contact for Personalis:

Jennifer Havlek  
[pr@personalis.com](mailto:pr@personalis.com)  
[www.personalis.com](http://www.personalis.com)

650-752-1300

Source: Personalis, Inc.